Abstract
We have not added the abstract for this poster yet. The publisher's page has the full record.
MPC-7869, a selective Abeta42-lowering agent, delays time to clinically significant psychiatric adverse events in Alzheimer's disease: analysis from a 12-month phase 2 trial
Presented as a poster exhibit at the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain Published January 1, 2006
More on these topics
Browse all publications →-
2026 · Alzheimers Dement
Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio-Hermes Study participants
-
2026 · The Journal of Prevention of Alzheimer's Disease
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
-
2025 · Journal of Alzheimer’s Disease
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial
-
2024 · Alzheimers Dement (N Y)
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease